Genky DrugStores Co., Ltd.
FY2026 Q2 Financial Results Presentation Materials
For FY2026 Q2, net sales amounted to 53.218 billion yen, a 9.3% increase year-over-year, operating income was 2.801 billion yen, up 20.6%, and the full-year earnings guidance has been revised upward to sales of 221.2 billion yen and operating income of 11.05 billion yen.
Key Figures
- Net Sales (2Q Actual): 53,218 million yen (Year-over-Year +9.3%)
- Operating Income (2Q Actual): 2,801 million yen (Year-over-Year +20.6%)
- Full-Year Operating Income Forecast (Revised): 11,050 million yen (Year-over-Year +14.4%)
AI要約
Performance Overview
For FY2026 Q2, net sales totaled 53,218 million yen, a 9.3% increase year-over-year, and operating income reached 2,801 million yen, up 20.6%. Gross profit margin improved to 20.54% from 20.13% in the same period last year. Although selling, general and administrative expenses underperformed compared to the plan, appropriate control of working hours led to operating income exceeding the plan by 140 million yen. New store openings numbered 17, nearly on target with the initial plan of 18 stores. Same-store sales rose steadily by 2.5%, slightly below the planned 2.6% increase.
Revision of Full-Year Earnings Guidance
The full-year earnings guidance for FY2026 has been revised, with net sales forecasted at 221.2 billion yen (up 10.2% year-over-year) and operating income projected at 11.05 billion yen (up 14.4%). Gross profit margin is assumed at 20.4%, and SG&A expense ratio at 15.4%. The plan includes 61 new store openings and 3 store closures (including large-scale stores). Earnings per share (EPS) is expected to be 257.5 yen. The company aims to improve sales and operating income per unit area through its EDLP strategy while continuing to reduce expense ratios.
